RBC Capital on Regeneron (REGN): 'We see potential earlier-than-expected launch of biosimilar product as incrementally negative to REGN's story'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $1,282.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
